The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II multicenter trial of mFOLFOX6 as adjuvant treatment after resection of liver metastases from colorectal cancer (Miyagi-HBPCOG Trial-001): The final data of progression-free survival.
Yu Katayose
No relevant relationships to disclose
Kuniharu Yamamoto
No relevant relationships to disclose
Shinichi Takemura
No relevant relationships to disclose
Michinaga Takahashi
No relevant relationships to disclose
Ryuji Nakamura
No relevant relationships to disclose
Hiromune Shimamura
No relevant relationships to disclose
Taku Asanuma
No relevant relationships to disclose
Tetsuyuki Uchiyama
No relevant relationships to disclose
Kojin Endo
No relevant relationships to disclose
Masaya Oikawa
No relevant relationships to disclose
Kenichi Shiiba
No relevant relationships to disclose
Kei Nakagawa
No relevant relationships to disclose
Shinichi Egawa
No relevant relationships to disclose
Michiaki Unno
No relevant relationships to disclose